SCHEMBL697388

SCHEMBL697388

O=COC1(c2cccc(Br)c2)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
CTSD P07339 1/20 0.35
BACE1 P56817 1/20 0.35
HSD11B1 P28845 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
GAA P10253 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
CISD1 Q9NZ45 3/20 0.33
MAOB P27338 3/20 0.33
MAOA P21397 2/20 0.33
CHRNA1 P02708 1/20 0.33
CHRNG P07510 1/20 0.33
CHRNB1 P11230 1/20 0.33
CHRNB2 P17787 1/20 0.33
SLC6A2 P23975 1/20 0.33
CHRNB4 P30926 1/20 0.33
SLC6A4 P31645 1/20 0.33
CHRNA3 P32297 1/20 0.33
CHRNA4 P43681 1/20 0.33
SLC6A3 Q01959 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16322010 0.79 CYP2A6 (0.35) HSD11B1MAOBMAOAPIM1PIM2
SCHEMBL696139 0.79 SLC6A3 (0.42) HSD11B1CHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL27915428 0.78 ALOX5 (0.43) ALDH1A1CTSDBACE1HSD11B1CHRNA1
SCHEMBL348386 0.77 MEN1 (0.39) MAOBMAOA
SCHEMBL28647910 0.75 PARP1 (0.43) ALDH1A1CTSDBACE1SMN1; SMN2GAA
SCHEMBL30605856 0.74 ALDH1A1 (0.44) ALDH1A1CTSDBACE1HSD11B1SMN1; SMN2
SCHEMBL29089813 0.74 ALDH1A1 (0.44) ALDH1A1CTSDBACE1HSD11B1SMN1; SMN2
SCHEMBL5182694 0.72 SLC6A4 (0.44) ALDH1A1HSD11B1GAANPSR1SLC6A2
SCHEMBL16321554 0.72 KDM1A (0.33)
SCHEMBL19357460 0.71 ALDH1A1 (0.41) ALDH1A1CTSDBACE1HSD11B1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 ALDH1A1 727/4885CTSD 1583/4885BACE1 1447/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.